
1 Discussion

This is a first in silico study directly comparing clinical stereotactic body radiation therapy (SBRT) with scanned carbon-ions (PT) treatment plans for non-small cell lung cancer (NSCLC). Our results show, that carbon-ions could be considered an alternative to SBRT, with the same tumor coverage and less dose to OAR.

Since PT offers a precise dose shaping, it can be more prone to uncertainties and a special consideration must be paid to them. Calculation of time-resolved (4D) doses can be significantly affected by errors in deformable image registration (DIR) **Citat**. Special tools were developed in the scope of this thesis to ensure DIR quality assurance (DIRQA). Additionally, DIRQA was tested on a large dataset for a tool verification. Treatment of NSCLC with PT is also influenced by interplay between tumor motion and beam scanning. It was shown that rescanning offers an adequate motion mitigation. Additionally, a prospect for treating patients with multiple lung metastases was displayed.

1.1 Deformable image registration

With features such as adaptive treatment planning [Yan et al., 1997], 4D optimization [Trofimov et al., 2005], 4D dose calculation [Flampouri et al., 2006], contour propagation [Lu et al., 2006] and combining different imaging modalities [Leibfarth et al., 2013] DIR is slowly entering everyday clinical work-flow. There are various different registration algorithms available [Varadhan et al., 2013] along with different optimization metrics, such as mean square error, cross-correlation, or normalized mutual information [Glocker et al., 2011].

The advantage of using open-source software for DIR, as explained in Section ??, is that different DIR algorithms, optimization metrics and image types can be used. Either with using existing libraries, such as ITK [Yoo et al., 2002], or by writing designated software [Fedorov et al., 2015]. A B-Spline algorithm was used for DIR in this thesis. There are large deformations present in lung and cardiac 4D-CT, which B-Spline should handle well [Tang et al., 2013]. The mean square error metric also gives better results for images of the same modality and same contrast [Varadhan et al., 2013]. The comparison between different algorithms and optimization metrics is beyond the scope of this thesis.

1.1.1 Deformable image registration validation

Any DIR algorithm must undergo thorough evaluation before it can be used clinically. The most common practice for DIRQA is visual validation [Stanley et al., 2013]. Our DIRQA module offers false color, checkerboard and landmarks distance as visual validation methods. Contour validation is currently lacking in our DIRQA module. In literature many different attempts have been done to assess DIRQA with landmarks or contours. A study by Hardcastle et al [Hardcastle et al., 2012] compared demons and Salient-Feature-Based registration with dice coefficient between propagated and physician drawn contours. A multi-institutional study by Brock et al [Brock, 2010] compared differences in propagated and oncologist drawn landmarks. A method has been developed by Castillo et al [Castillo et al., 2009] to automatically identify landmark points in lung patients images. However, visual based evaluations are limited in regions of uniform image intensity and by the number of the objects being tracked [Kashani et al., 2008, Liu et al., 2012]. An example of visual validation disadvantage could be seen in pig cardiac 4D-CT, where visual evaluation did not show any errors in DIR, but errors were observed in vector fields resulting from DIR.

An alternative to visual validation is to evaluate mathematical properties of vector fields. The two most common DIR vector fields evaluation metrics are Jacobian determinant (Jacobian) and inverse consistency error (ICE) [Leow et al., 2007, Christensen and Johnson, 2001], which we also implemented. We have shown that bigger deformations yield more deviations in Jacobian and ICE, which was also found by Stanley et al [Stanley et al., 2013]. Furthermore, we have confirmed that Jacobian should always be positive for a successful DIR [Rey et al., 2002]. Additionally, our results show that ICE should be smaller than maximum vector field magnitudes. Any deviation from this checks should be thoroughly examined.

There are additional vector fields validation methods beside Jacobian and ICE, such as vector field curl [Schreibmann et al., 2012], unbalanced energy [Zhong et al., 2007], permutation and analysis of variance (ANOVA) tests [Klein et al., 2009]. It was demonstrated in a study by Salguero et al that DIR errors greater than 1 mm can lead to large dose errors in high-dose gradient regions. Therefore the DIR accuracy has to be quantified at each image voxel in the high-dose gradient regions. A solution to evaluate at each specific voxel and for patient-specific registration was given by Stanley et al [Stanley et al., 2013]. They proposed a computational phantoms and their deformations with a finite element module framework.

1.2 Radiation treatment for non-small cell lung cancer

1.2.1 Non-small cell lung cancer early stage

Surgery is the gold standard in treating NSCLC in the early stages [Roesch et al., 2014]. In recent years, however, SBRT showed similar results as surgery and SBRT is recommended for all high-risk surgical patients. In a recent comparison study by Yu et al [Yu et al., 2015], SBRT had lower intermediate mortality and toxicity, compared to surgery. However, patients with long life expectancies were found to benefit more from surgery.

There are several clinical scenarios where use of SBRT might be limited. This include treatment of centrally located tumors, tumors close to chest wall, large tumors (radius > 5 cm) and multiple primary tumors [Timmerman et al., 2006, Georg et al., 2008, Westover et al., 2012]. The limitation of SBRT could open possibilities to other treatment modalities, such as particle therapy. Interestingly, two of the mentioned scenarios, large tumors and multiple tumors, would benefit the most from particle therapy, according to the results shown in this thesis and to the results published by Kadoya et al [Kadoya et al., 2010]. In a study done at Francis H. Burr Proton Therapy Center patients who could not be treated with SBRT, due to the scenarios mentioned, were treated with passive proton beam in 3 - 5 fractions, delivering 42 - 50 Gy [Westover et al., 2012]. They observed similar tumor local control rates as in SBRT (100% in a two year follow-up) with limited toxicities. It should be noted, that the patients treated were rejected from SBRT treatment.

1.2.2 Non-small cell lung cancer advanced stage

While treatment for early stage NSCLC is well established, more than 75% NSCLC cases present themselves in an advance stage [Jemal et al., 2009], usually due to the lack of detection in the early stages. The standard of care for advanced NSCLC is concurrent chemotherapy [Oshiro et al., 2014]. Dose escalation studies showed favorable prognosis for doses higher than 70 Gy [Hayman et al., 2001, Rosenman et al., 2002, Socinski et al., 2008]. The results of recent phase 3 randomized trial by Bradley et al [Bradley et al., 2010], however, showed better survival rates for patients delivered 60 Gy, instead of 74 Gy. It was speculated that higher doses to heart and esophagus might have contributed to higher mortality rates for patients who were administered higher doses [Cox, 2012]. Results presented in this thesis show that mean dose to heart and esophagus would be on average 1 Gy smaller with PT than with SBRT. Similar results were observed when comparing protons to SBRT [Georg et al., 2008].

In recent phase II study by Iyengar et al [Iyengar et al., 2014] they treated stage IV NSCLC with SBRT and chemotherapy. They have irradiated 52 targets in 24 patients, 16 of them had

more than one target. The results were promising, with 20 months median overall survival, compared to 9 months when treating with chemotherapy only [Tsao, 2016]. Results in this thesis show, that patients with multiple sites would especially benefit from PT. Based on the poor prognosis that stage IV NSCLC patients have and on the results published by Iyengar et al., stage IV NSCLC patients could be eligible candidates for PT treatment. Additionally, such patients usually exhibit chronic obstructive pulmonary disease and less dose to lung is warranted [Westover et al., 2012]. This further supports our claim, since our study showed substantial differences in doses to ipsilateral lung ($V_{20\%}$ was on average 5% smaller for PT) and contralateral lung as well - 70% of patients did not receive any dose to contralateral lung, whereas SBRT deposited dose in contralateral lung in all patients. The PT treatment planning for patients with complex geometry has to include 4D optimization and dose calculation as shown within this thesis. The treatment plan after optimization can respect the OAR dose limits, while 4D dose can exceed them. Beam tracking or jet-ventilation would be possible solutions, however, they significantly complicate treatment.

The results of multi-institutional randomized trial, comparing photons and particle therapy in treating NSCLC, will have an important impact on treating NSCLC [RTOG, 2014]. The trial started in 2014 and we can not expect results before 2020.

1.2.3 Motion mitigation

1.2.4 Outlook

4pi adaptive tracking

RBE

24Gy(RBE)

Hypo-fractionation of liver cancer

Future SBRT - 4pi SBRT in lung cancer will become standard

Overview of lung cancer

Reoccurrent lung cancer

Heart and esophagus dose good predictors of mortality RTOG 0917 median survival 19.5 months vs 29.4 months with protons (<http://www.ncbi.nlm.nih.gov/pubmed/24864278>) for 74 Gy, but was 29 for 60 Gy with photons as well.

Photons vs Protons for stage III NSCLC RTOG 1308

Stephen Bowen - deliver more dose to damaged lung instead of functionated one

bio-adaptive particle therapy

SBRT is the lowest for cost per quality of life for early stage, but Protons beams scanning for advanced SBRT limited: large tumors (>5 cm, more tumors, patients with poor lung function)

Proton SBRT

Seattle treated NSCLC with PBS
ABS vs passive?
Small tumor are bad
dosimetric study of protons vs sbrt



Bibliography

- [Bradley et al., 2010] Bradley, J. D., Bae, K., Graham, M. V., Byhardt, R., Govindan, R., Fowler, J., Purdy, J. A., Michalski, J. M., Gore, E., and Choy, H. (2010). Primary analysis of the phase ii component of a phase i/ii dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: Rtog 0117. *Journal of Clinical Oncology*, 28(14):2475–2480.
- [Brock, 2010] Brock, K. K. (2010). Results of a multi-institution deformable registration accuracy study (midras). *Int. J. Radiat. Oncol. Biol. Phys.*, 76(2):583–596.
- [Castillo et al., 2009] Castillo, R., Castillo, E., Guerra, R., Johnson, V. E., McPhail, T., Garg, A. K., and Guerrero, T. (2009). A framework for evaluation of deformable image registration spatial accuracy using large landmark point sets. *Physics in Medicine and Biology*, 54(7):1849.
- [Christensen and Johnson, 2001] Christensen, G. E. and Johnson, H. J. (2001). Consistent image registration. *IEEE Transactions on Medical Imaging*, 20(7):568–582.
- [Cox, 2012] Cox, J. D. (2012). Are the results of rtog 0617 mysterious? *International Journal of Radiation Oncology*, 82(3):1042–1044.
- [Fedorov et al., 2015] Fedorov, A., Khallaghi, S., Sánchez, C., Lasso, A., Fels, S., Tuncali, K., Sugar, E. N., Kapur, T., Zhang, C., Wells, W., Nguyen, P., Abolmaesumi, P., and Tempany, C. (2015). Open-source image registration for mri-trus fusion-guided prostate interventions. *Int J Comput Assist Radiol Surg*, 10(6):925–34.
- [Flampouri et al., 2006] Flampouri, S., Jiang, S., Sharp, G. C., Wolfgang, J., Patel, A. A., and Choi, N. C. (2006). Estimation of the delivered patient dose in lung imrt treatment based on deformable registration of 4d-ct data and monte carlo simulations. *Phys Med Biol*, 51(11):2763–2779.
- [Georg et al., 2008] Georg, D., Hillbrand, M., Stock, M., Dieckmann, K., and Pötter, R. (2008). Can protons improve sbrt for lung lesions?: Dosimetric considerations. *Radiotherapy and Oncology*, 88(3):368–375.
- [Glocker et al., 2011] Glocker, B., Sotiras, A., Komodakis, N., and Paragios, N. (2011). *Annu Rev Biomed Eng*.
- [Hardcastle et al., 2012] Hardcastle, N., Tomé, W. A., Cannon, D. M., Brouwer, C. L., Witten-dorp, P. W., Dogan, N., Guckenberger, M., Allaire, S., Mallya, Y., Kumar, P., Oechsner, M.,

- Richter, A., Song, S., Myers, M., Polat, B., and Bzdusek, K. (2012). A multi-institution evaluation of deformable image registration algorithms for automatic organ delineation in adaptive head and neck radiotherapy. *Radiat Oncol*, 7:90–90. 1748-717X-7-90[PII].
- [Hayman et al., 2001] Hayman, J. A., Martel, M. K., Ten Haken, R. K., Normolle, D. P., Todd, R. F., Littles, J. F., Sullivan, M. A., Possert, P. W., Turrisi, A. T., and Lichter, A. S. (2001). Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase i trial. *Journal of Clinical Oncology*, 19(1):127–136.
- [Iyengar et al., 2014] Iyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Camidge, D. R., Gaspar, L. E., Doebele, R. C., Bunn, P. A., Choy, H., and Timmerman, R. (2014). Phase ii trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. *J.Clin.Oncol.*, 32(34):3824–3854.
- [Jemal et al., 2009] Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009). Cancer statistics, 2009. *CA: A Cancer Journal for Clinicians*, 59(4):225–249.
- [Kadoya et al., 2010] Kadoya, N., Obata, Y., Kato, T., Kagiya, M., Nakamura, T., Tomoda, T., Takada, A., Takayama, K., and Fuwa, N. (2010). Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. *Int.J.Radiat.Oncol.Biol.Phys.*, 79(4):1225–1231.
- [Kashani et al., 2008] Kashani, R., Hub, M., Balter, J. M., Kessler, M. L., Dong, L., Zhang, L., Xing, L., Xie, Y., Hawkes, D., Schnabel, J. A., McClelland, J., Joshi, S., Chen, Q., and Lu, W. (2008). Objective assessment of deformable image registration in radiotherapy: A multi-institution study. *Medical Physics*, 35(12):5944–5953.
- [Klein et al., 2009] Klein, A., Andersson, J., Ardekani, B. A., Ashburner, J., Avants, B., Chiang, M.-C., Christensen, G. E., Collins, D. L., Gee, J., Hellier, P., Song, J. H., Jenkinson, M., Lepage, C., Rueckert, D., Thompson, P., Vercauteren, T., Woods, R. P., Mann, J. J., and Parsey, R. V. (2009). Evaluation of 14 nonlinear deformation algorithms applied to human brain mri registration. *Neuroimage*, 46(3):786–802.
- [Leibfarth et al., 2013] Leibfarth, S., Mönnich, D., Welz, S., Siegel, C., Schwenzer, N., Schmidt, H., Zips, D., and Thorwarth, D. (2013). A strategy for multimodal deformable image registration to integrate pet/mr into radiotherapy treatment planning. *Acta Oncologica*, 52(7):1353–1359. PMID: 23879651.
- [Leow et al., 2007] Leow, A. D., Yanovsky, I., Chiang, M. C., Lee, A. D., Klunder, A. D., Lu, A., Becker, J. T., Davis, S. W., Toga, A. W., and Thompson, P. M. (2007). Statistical properties of jacobian maps and the realization of unbiased large-deformation nonlinear image registration. *IEEE Trans Med*, 26:822–832.

-
- [Liu et al., 2012] Liu, F., Hu, Y., Zhang, Q., Kincaid, R., Goodman, K. A., and Mageras, G. S. (2012). Evaluation of deformable image registration and motion model in ct images with limited features. *Phys Med Biol*, 57(9):2539–2554. 22491010[pmid].
- [Lu et al., 2006] Lu, W., Olivera, G. H., Chen, Q., Chen, M. L., and Ruchala, K. J. (2006). Automatic re-contouring in 4d radiotherapy. *Phys Med Biol*, 51(5):1077–1099.
- [Oshiro et al., 2014] Oshiro, Y., Okumura, T., Kurishima, K., Homma, S., Mizumoto, M., Ishikawa, H., Onizuka, M., Sakai, M., Goto, Y., Hizawa, N., Sato, Y., and Sakurai, H. (2014). High-dose concurrent chemo–proton therapy for stage iii nscl: preliminary results of a phase ii study. *Journal of Radiation Research*, 55(5):959–965.
- [Rey et al., 2002] Rey, D., Subsol, G., Delingette, H., and Ayache, N. (2002). Automatic detection and segmentation of evolving processes in 3d medical images: application to multiple sclerosis. *Med Image Anal*, 6(2):163–179.
- [Roesch et al., 2014] Roesch, J., Andratschke, N., and Guckenberger, M. (2014). Sbrt in operable early stage lung cancer patients. *Transl Lung Cancer Res*, 3(4):212–224. tlc-03-04-212[PII].
- [Rosenman et al., 2002] Rosenman, J. G., Halle, J. S., Socinski, M. A., Deschesne, K., Moore, D. T., Johnson, H., Fraser, R., and Morris, D. E. (2002). High-dose conformal radiotherapy for treatment of stage iiia/iiib non-small-cell lung cancer: technical issues and results of a phase i/ii trial. *International Journal of Radiation Oncology*, 54(2):348–356.
- [RTOG, 2014] RTOG (2014). Rtog 1308 protocol information: Phase iii randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage ii-iiib nscl.
- [Schreibmann et al., 2012] Schreibmann, E., Pantalone, P., Waller, A., and Fox, T. (2012). A measure to evaluate deformable registration fields in clinical settings. *Journal of Applied Clinical Medical Physics*, 13(5).
- [Socinski et al., 2008] Socinski, M. A., Blackstock, A. W., Bogart, J. A., Wang, X., Munley, M., Rosenman, J., Gu, L., Masters, G. A., Ungaro, P., Sleeper, A., Green, M., Miller, A. A., and Vokes, E. E. (2008). Randomized phase ii trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 gy) in stage iii non–small-cell lung cancer: Calgb 30105. *Journal of Clinical Oncology*, 26(15):2457–2463.
- [Stanley et al., 2013] Stanley, N., Glide-Hurst, C., Kim, J., Adams, J., Li, S., Wen, N., Chetty, I. J., and Zhong, H. (2013). Using patient-specific phantoms to evaluate deformable image registration algorithms for adaptive radiation therapy. *J Appl Clin Med Phys*, 14(6):4363–4363.

-
- [Tang et al., 2013] Tang, C., Xie, X., and Du, R. (2013). Improved image registration technique using demons and b-spline. *Biomedical and Biotechnology Engineering*, 3(A).
- [Timmerman et al., 2006] Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., Ewing, M., Abdulrahman, R., DesRosiers, C., Williams, M., and Fletcher, J. (2006). Excessive toxicity when treating central tumors in a phase ii study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *Journal of Clinical Oncology*, 24(30):4833–4839.
- [Trofimov et al., 2005] Trofimov, A., Rietzel, E., Lu, H. M., Martin, B., Jiang, S., Chen, G. T., and Bortfeld, T. (2005). Temporo-spatial imrt optimization: concepts, implementation and initial results. *Phys Med Biol*, 50(12):2779–2798.
- [Tsao, 2016] Tsao, A. S. (2016). Lung carcinoma. Merck Manual Professional Edition.
- [Varadhan et al., 2013] Varadhan, R., Karangelis, G., K., K., and Hui, S. (2013). A framework for deformable image registration validation in radiotherapy clinical applications. *J Appl Clin Med Phys*, 14(1).
- [Westover et al., 2012] Westover, K. D., Seco, J., Adams, J. A., Lanuti, M., Choi, N. C., Engelman, M., and Willers, H. (2012). Proton sbrt for medically inoperable stage i nslc. *J Thorac Oncol*, 7(6):1021–1025. 22551902[pmid].
- [Yan et al., 1997] Yan, D., Vicini, F., Wong, J., and Martinez, A. (1997). Adaptive radiation therapy. 42(1):123–132.
- [Yoo et al., 2002] Yoo, T. S., Ackerman, M. J., Lorensen, W. E., Schroeder, W., Chalana, V., Aylward, S., Metaxas, D., and Whitaker, R. (2002). Engineering and algorithm design for an image processing api: a technical report on itk—the insight toolkit. *Stud Health Technol Inform*, 85:586–592.
- [Yu et al., 2015] Yu, J. B., Soulos, P. R., Cramer, L. D., Decker, R. H., Kim, A. W., and Gross, C. P. (2015). Comparative effectiveness of surgery and radiosurgery for stage i non-small cell lung cancer. *Cancer*, 121(14):2341–2349.
- [Zhong et al., 2007] Zhong, H., Peters, T., and Siebers, J. V. (2007). Fem-based evaluation of deformable image registration for radiation therapy. *Physics in Medicine and Biology*, 52(16):4721.